Study CO40939 is an ongoing Phase 1b study that enrolled patients with advanced MSS-CRC with high CEACAM5 expression treated with cibisatamab at the RP2D in combination with atezolizumab after pretreatment with obinutuzumab (NCT03866239). This evidence concerns the gene CEACAM5 and colorectal carcinoma.